Small conductance calcium-activated potassium channel current, IKCa, has
IntroductionAtrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting 3% of the adult population of developed countries. AF is associated with increased morbidity and mortality and its incidence is expected to rise in the near future, making it an urgent and important health problem [1].Although anti-arrhythmic drugs (AADs) are the first line therapy for recent onset AF, their cardioversion efficacy can be as low as 50% [1]. AADs often carry significant side effects, namely the potential to induce lifethreatening ventricular arrhythmias. These pro-arrhythmic side effects can be minimised if AADs are designed to target atrial-selective ionic channels, which have a negligible contribution to the ventricular action potential.One of such targets is the K + ultra-rapid delayed rectifier current, IKur, which is expressed in human atrial cells, but not in human ventricles [2]. This is in contrast with the rapid delayed rectifier current, IKr, which is ubiquitous throughout the heart and the blockade of which may lead to life-threatening Torsade de Pointes [2].Recently, ionic current carried by small-conductance calcium-dependent K + channels, IKCa, has been characterised in human and canine atrial cells, but, significantly, not in ventricular myocytes, making IKCa a potentially desirable target of anti-arrhythmic drug action in AF. Genomic associations between IKCa and AF have also been established [3].Although blocking IKCa is known to increase the action potential duration (APD) in canine atrial cells [3]-[6], there is some controversy as to whether its blockade is proor anti-arrhythmic. Blocking IKCa has been found to facilitate the initiation of atrial arrhythmias [3], [6], by increasing both APD and APD heterogeneity in the canine left atrium (LA). Other studies have instead found that IKCa blockade, through prolongation of APD, led to reduced AF duration [4] and AF termination [5]. It is also at the moment not clear whether IKCa is overexpressed in the presence of AF remodelling [4] or not [7].In this paper, we aim to reconcile the disparate experimental findings about IKCa's effect on AF using insights from computational models. To this end, we introduce a new mathematical formulation for IKCa and include it in our recently developed canine atrial cell models [8]. We use these updated canine models to investigate the effect on APD of blockades of IKr, IKur and IKCa in several atrial remodelling conditions. We then determine the effectiveness of these blockades in realistic 3D canine atrial models [8] and interpret these findings in the light of the drugs' effects on APD and APD dispersion across the entire atria, using the formalism previously applied to investigate the effectiveness of multi-channelblocking AADs [8].